Abstract 472P
Background
Esophageal squamous cell carcinoma (ESCC) has a poor prognosis in Asian regions and the immunotherapy targeting PD-1 is on the stage of clinical trials. This study aims to investigate the prognostic effect of PD-1 expression in intratumoral and stromal tumor-infiltrating lymphocytes (TILs) on relapse and overall survival of ESCC patients.
Methods
A retrospective cohort study was conducted with recruiting 142 ESCC patients who received surgical treatment. Intratumoral and stromal PD-1 expression was tested by immunohistochemistry (IHC).
Results
The median follow-up time was 22 months and 21.1% patients were lost of follow-up. Cell counts and expression rate of intratumoral PD1+ TILs did not show any association with disease-free survival (DFS) and overall survival (OS). Expression rate of stromal PD1+ TILs did not have a significant relationship with DFS. The patients with expression rate of stromal PD1+ TILs >20% had the median OS being 19 months and the patients with expression rate ≤20% did not achieved median OS (p = 0.034). The adjusted HR of higher expression rate was 1.49 (95%CI 0.82, 2.60, p = 0.189) for OS. ESCC patients with ≤18 stromal PD1+ TILs/HPF had the median DFS being 10 months however the patients with >18 cells/HPF had the median DFS being 48 months (p = 0.037). The adjusted HR of > 18 stromal PD1+ TILs/HPF on DFS was 0.59 (95%CI 0.35, 1.01, p = 0.055). With reference to the patients of lower expression rate/higher cell counts of stromal PD1+ TILs, patients with lower expression rate/lower cell counts, higher expression rate/higher cell counts, and higher expression rate/lower cell counts, had the adjusted HR for DFS increased to 3.73, 3.36 and 3.99 (p for trend being 0.030) and the adjusted HRs for OS increased to 2.95, 3.64 and 3.82 (p for trend being 0.015), respectively.
Conclusions
Integration of expression rate and cell counts of stromal PD1+ TILs had a significant prognostic effect in terms of relapse and overall survival. Further studies are warranted to provide reference for immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Beijing Hospitals Authority.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
184P - Expression pattern of CDK12 protein in gastric cancer and its positive correlation with CD8+ cell density and CCL12 expression
Presenter: Jun Ji
Session: Poster display session
Resources:
Abstract
185P - Evaluation of the effect of cholesorption on the concentration of TNF-α in the serum of the blood in tumours of the biliopancreatoduodenal zone
Presenter: Marufjon Salokhiddinov
Session: Poster display session
Resources:
Abstract
186P - Efficacy and safety of sorafenib following hepatic resection in patients with hepatocellular carcinoma: A meta-analysis
Presenter: Yang Yuan
Session: Poster display session
Resources:
Abstract
187P - Correlation between spleenic dose and grade of hematological toxicity in chemoradiation of stomach
Presenter: Umesh Velu
Session: Poster display session
Resources:
Abstract
188P - Survival and prognostic factors in cholangiocarcinoma: A single-center experience
Presenter: Sonngwit Payapwattanawong
Session: Poster display session
Resources:
Abstract
189P - Stereotactic body radiotherapy in primary hepatocellular carcinoma and oligometastatis to liver: A single Institution experience
Presenter: Sayan Paul
Session: Poster display session
Resources:
Abstract
190P - Details of response with first-line gemcitabine and nab-paclitaxel therapy in patients with advanced pancreatic cancer
Presenter: Yusuke Nagata
Session: Poster display session
Resources:
Abstract
191P - Assessment of efficacy and safety of sorafenib versus no treatment in Egyptian hepatocellular carcinoma patients
Presenter: Noha El Baghdady
Session: Poster display session
Resources:
Abstract
192P - Clinical importance of the determination of interleukin-6 in bile and blood in tumours of biliopancreatoduodenal zone
Presenter: Marufjon Salokhiddinov
Session: Poster display session
Resources:
Abstract
193P - Metastatic carcinoma gall bladder: A clinicoepidemiological profile of Indian patients
Presenter: Anvesh Rathore
Session: Poster display session
Resources:
Abstract